Skip to main content
. 2015 Nov 26;16(12):28108–28122. doi: 10.3390/ijms161225997

Figure 6.

Figure 6

SPARC and Endothelin 1 (ET-1)/ETAR in tissue specimens from patients without bone metastasis development. For Patients 4 and 5, representative images of immunohistochemical staining for SPARC and ET-1/ETAR in dysplastic lesions, associated with ductal breast carcinoma, are shown. Negative controls were assayed without the specific antibody.